Table 3.
1-year clinical outcomes in propensity score matched patients
| Outcomes | SGLT2i group | DPP-4i group | Unadjusted analysis | IPTW-adjusted analysis | ||
|---|---|---|---|---|---|---|
| (n = 186) | (n = 593) | HR (95% CI) | p -value | HR (95% CI) | p -value | |
| MACE | 19 (10.2) | 58 (9.8) | 0.96 (0.57–1.61) | 0.873 | 0.99 (0.46–2.14) | 0.983 |
| All-cause mortality | 0 (0.0) | 11 (1.8) | NA | NA | NA | NA |
| Cardiac death | 0 (0.0) | 5 (0.8) | NA | NA | NA | NA |
| Non-cardiac death | 0 (0.0) | 6 (1.0) | NA | NA | NA | NA |
| Myocardial infarction | 2 (1.1) | 9 (1.5) | 1.47 (0.32–6.82) | 0.621 | 2.78 (0.31–24.90) | 0.362 |
| Any revascularization | 12 (6.4) | 22 (3.7) | 0.56 (0.28–1.13) | 0.108 | 0.68 (0.26–1.74) | 0.418 |
| CVA | 4 (2.1) | 8 (1.3) | 0.67 (0.20–2.23) | 0.513 | 1.43 (0.24–8.71) | 0.697 |
| Rehospitalization | 3 (1.6) | 19 (3.2) | 2.05 (0.61–6.94) | 0.247 | 1.58 (0.28–8.99) | 0.603 |
Categorical values are presented as percentage (number)
CI = confidence interval; CVA = cerebrovascular accident; DPP-4i = dipeptidyl peptidase-4 inhibitors; HR = hazard ratio; NA = not applicable; IPTW = inverse probability of treatment weighting; MACE = major adverse composite event; SGLT2i = sodium-glucose cotransporter 2 inhibitors